Carpenter W T, Schooler N R, Kane J M
Department of Psychiatry, University of Maryland School of Medicine, Baltimore, USA.
Arch Gen Psychiatry. 1997 May;54(5):401-7. doi: 10.1001/archpsyc.1997.01830170015002.
Schizophrenia research is receiving intense scrutiny from an ethical perspective. Medication-free protocols present a most vexing dilemma in that they greatly enhance the opportunity for advancing knowledge but also raise the prospect of withholding known effective treatment. In this article, we discuss the purpose of medication-free protocols in new drug development and nontreatment research. Potential benefits and risks associated with drug discontinuation are evaluated, and methods for minimizing risk and increasing benefits are proposed as guidelines for the protection of individual subjects. The complex problem of informed consent also is addressed. Medication-free research in schizophrenia is difficult, but it can be conducted relatively, safely with freely consenting, competent subjects. Assurance that studies meet this standard is required. We believe that such investigations can meet high standards of ethics and subject protection, and that a radical revision of procedures for research review and implementation is not indicated.
从伦理角度来看,精神分裂症研究正受到密切审视。无药物治疗方案带来了一个极其棘手的困境,因为它们极大地增加了推进知识的机会,但同时也引发了不提供已知有效治疗的可能性。在本文中,我们讨论了无药物治疗方案在新药开发和非治疗性研究中的目的。评估了与停药相关的潜在益处和风险,并提出了将风险降至最低和增加益处的方法,作为保护个体受试者的指导方针。还讨论了知情同意这一复杂问题。精神分裂症的无药物治疗研究很困难,但在获得自由同意且具备行为能力的受试者参与的情况下,可以相对安全地进行。需要确保研究符合这一标准。我们认为,此类研究能够达到伦理和受试者保护的高标准,并不需要对研究审查和实施程序进行彻底修订。